Early experience with targeted therapy and dendritic cell vaccine in metastatic renal cell carcinoma after nephrectomy

PURPOSE: Metastatic renal cell carcinoma (RCC) is one of the most treatment-resistant malignancies and nephrectomy, isolated or combined with systemic chemotherapy typically has limited or no effectiveness. We report our initial results in patients treated with the association of molecular targeted therapy, nephrectomy, and hybrid dendritic-tumor cell (DC) vaccine. MATERIALS AND METHODS: Two male patients diagnosed with metastatic RCC were selected for the study. They were treated with the triple strategy, in which sunitinib (50 mg per day) was given for 4 weeks, followed by radical nephrectomy after two weeks. DC vaccine was initiated immediately after surgery and repeated monthly. Sunitinib was restarted daily after 2 to 3 weeks of surgery with a 7-day interval every 4 weeks. RESULTS: Both patients had complete adherence to the proposed treatment with DC vaccine therapy combined with sunitinib. Follow-up in these patients at 9 and 10 months demonstrated a stable disease in both, as shown by imaging and clinical findings, with no further treatment required. CONCLUSION: The immune response obtained with DC vaccine combined with the antiangiogenic effect of sunitinib and the potential benefits of cytoreductive nephrectomy in advanced disease could represent a new option in the treatment of metastatic RCC. Further prospective trials are needed not only to elucidate the ideal dosing and schedule, but also to better define the proof-of-concept proposed in this report and its role in clinical practice.

Saved in:
Bibliographic Details
Main Authors: Dall'Oglio,Marcos F., Sousa-Canavez,Juliana M., Tanno,Fabio Y., Tiseo,Bruno C., Crippa,Alexandre, Reis,Sabrina T. dos, Leite,Katia R. M., Srougi,Miguel
Format: Digital revista
Language:English
Published: Sociedade Brasileira de Urologia 2011
Online Access:http://old.scielo.br/scielo.php?script=sci_arttext&pid=S1677-55382011000200004
Tags: Add Tag
No Tags, Be the first to tag this record!
id oai:scielo:S1677-55382011000200004
record_format ojs
spelling oai:scielo:S1677-553820110002000042011-05-30Early experience with targeted therapy and dendritic cell vaccine in metastatic renal cell carcinoma after nephrectomyDall'Oglio,Marcos F.Sousa-Canavez,Juliana M.Tanno,Fabio Y.Tiseo,Bruno C.Crippa,AlexandreReis,Sabrina T. dosLeite,Katia R. M.Srougi,Miguel renal cell carcinoma dendritic cells neoplasm metastasis PURPOSE: Metastatic renal cell carcinoma (RCC) is one of the most treatment-resistant malignancies and nephrectomy, isolated or combined with systemic chemotherapy typically has limited or no effectiveness. We report our initial results in patients treated with the association of molecular targeted therapy, nephrectomy, and hybrid dendritic-tumor cell (DC) vaccine. MATERIALS AND METHODS: Two male patients diagnosed with metastatic RCC were selected for the study. They were treated with the triple strategy, in which sunitinib (50 mg per day) was given for 4 weeks, followed by radical nephrectomy after two weeks. DC vaccine was initiated immediately after surgery and repeated monthly. Sunitinib was restarted daily after 2 to 3 weeks of surgery with a 7-day interval every 4 weeks. RESULTS: Both patients had complete adherence to the proposed treatment with DC vaccine therapy combined with sunitinib. Follow-up in these patients at 9 and 10 months demonstrated a stable disease in both, as shown by imaging and clinical findings, with no further treatment required. CONCLUSION: The immune response obtained with DC vaccine combined with the antiangiogenic effect of sunitinib and the potential benefits of cytoreductive nephrectomy in advanced disease could represent a new option in the treatment of metastatic RCC. Further prospective trials are needed not only to elucidate the ideal dosing and schedule, but also to better define the proof-of-concept proposed in this report and its role in clinical practice.info:eu-repo/semantics/openAccessSociedade Brasileira de UrologiaInternational braz j urol v.37 n.2 20112011-04-01info:eu-repo/semantics/articletext/htmlhttp://old.scielo.br/scielo.php?script=sci_arttext&pid=S1677-55382011000200004en10.1590/S1677-55382011000200004
institution SCIELO
collection OJS
country Brasil
countrycode BR
component Revista
access En linea
databasecode rev-scielo-br
tag revista
region America del Sur
libraryname SciELO
language English
format Digital
author Dall'Oglio,Marcos F.
Sousa-Canavez,Juliana M.
Tanno,Fabio Y.
Tiseo,Bruno C.
Crippa,Alexandre
Reis,Sabrina T. dos
Leite,Katia R. M.
Srougi,Miguel
spellingShingle Dall'Oglio,Marcos F.
Sousa-Canavez,Juliana M.
Tanno,Fabio Y.
Tiseo,Bruno C.
Crippa,Alexandre
Reis,Sabrina T. dos
Leite,Katia R. M.
Srougi,Miguel
Early experience with targeted therapy and dendritic cell vaccine in metastatic renal cell carcinoma after nephrectomy
author_facet Dall'Oglio,Marcos F.
Sousa-Canavez,Juliana M.
Tanno,Fabio Y.
Tiseo,Bruno C.
Crippa,Alexandre
Reis,Sabrina T. dos
Leite,Katia R. M.
Srougi,Miguel
author_sort Dall'Oglio,Marcos F.
title Early experience with targeted therapy and dendritic cell vaccine in metastatic renal cell carcinoma after nephrectomy
title_short Early experience with targeted therapy and dendritic cell vaccine in metastatic renal cell carcinoma after nephrectomy
title_full Early experience with targeted therapy and dendritic cell vaccine in metastatic renal cell carcinoma after nephrectomy
title_fullStr Early experience with targeted therapy and dendritic cell vaccine in metastatic renal cell carcinoma after nephrectomy
title_full_unstemmed Early experience with targeted therapy and dendritic cell vaccine in metastatic renal cell carcinoma after nephrectomy
title_sort early experience with targeted therapy and dendritic cell vaccine in metastatic renal cell carcinoma after nephrectomy
description PURPOSE: Metastatic renal cell carcinoma (RCC) is one of the most treatment-resistant malignancies and nephrectomy, isolated or combined with systemic chemotherapy typically has limited or no effectiveness. We report our initial results in patients treated with the association of molecular targeted therapy, nephrectomy, and hybrid dendritic-tumor cell (DC) vaccine. MATERIALS AND METHODS: Two male patients diagnosed with metastatic RCC were selected for the study. They were treated with the triple strategy, in which sunitinib (50 mg per day) was given for 4 weeks, followed by radical nephrectomy after two weeks. DC vaccine was initiated immediately after surgery and repeated monthly. Sunitinib was restarted daily after 2 to 3 weeks of surgery with a 7-day interval every 4 weeks. RESULTS: Both patients had complete adherence to the proposed treatment with DC vaccine therapy combined with sunitinib. Follow-up in these patients at 9 and 10 months demonstrated a stable disease in both, as shown by imaging and clinical findings, with no further treatment required. CONCLUSION: The immune response obtained with DC vaccine combined with the antiangiogenic effect of sunitinib and the potential benefits of cytoreductive nephrectomy in advanced disease could represent a new option in the treatment of metastatic RCC. Further prospective trials are needed not only to elucidate the ideal dosing and schedule, but also to better define the proof-of-concept proposed in this report and its role in clinical practice.
publisher Sociedade Brasileira de Urologia
publishDate 2011
url http://old.scielo.br/scielo.php?script=sci_arttext&pid=S1677-55382011000200004
work_keys_str_mv AT dallogliomarcosf earlyexperiencewithtargetedtherapyanddendriticcellvaccineinmetastaticrenalcellcarcinomaafternephrectomy
AT sousacanavezjulianam earlyexperiencewithtargetedtherapyanddendriticcellvaccineinmetastaticrenalcellcarcinomaafternephrectomy
AT tannofabioy earlyexperiencewithtargetedtherapyanddendriticcellvaccineinmetastaticrenalcellcarcinomaafternephrectomy
AT tiseobrunoc earlyexperiencewithtargetedtherapyanddendriticcellvaccineinmetastaticrenalcellcarcinomaafternephrectomy
AT crippaalexandre earlyexperiencewithtargetedtherapyanddendriticcellvaccineinmetastaticrenalcellcarcinomaafternephrectomy
AT reissabrinatdos earlyexperiencewithtargetedtherapyanddendriticcellvaccineinmetastaticrenalcellcarcinomaafternephrectomy
AT leitekatiarm earlyexperiencewithtargetedtherapyanddendriticcellvaccineinmetastaticrenalcellcarcinomaafternephrectomy
AT srougimiguel earlyexperiencewithtargetedtherapyanddendriticcellvaccineinmetastaticrenalcellcarcinomaafternephrectomy
_version_ 1756428089422774272